



**HAL**  
open science

## Epidemiology and Control of BVD in the U.S.

Hana van Campen

► **To cite this version:**

Hana van Campen. Epidemiology and Control of BVD in the U.S.. *Veterinary Microbiology*, 2010, 142 (1-2), pp.94. 10.1016/j.vetmic.2009.09.049 . hal-00578405

**HAL Id: hal-00578405**

**<https://hal.science/hal-00578405>**

Submitted on 20 Mar 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Accepted Manuscript

Title: Epidemiology and Control of BVD in the U.S.

Author: Hana Van Campen

PII: S0378-1135(09)00466-0  
DOI: doi:10.1016/j.vetmic.2009.09.049  
Reference: VETMIC 4606

To appear in: *VETMIC*



Please cite this article as: Van Campen, H., Epidemiology and Control of BVD in the U.S., *Veterinary Microbiology* (2008), doi:10.1016/j.vetmic.2009.09.049

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 PROCEEDINGS FOR ESVV PESTIVIRUS 2008

2

3 Title: Epidemiology and Control of BVD in the U.S.

4 Author: Hana Van Campen

5 Affiliation: Department of Microbiology, Immunology and Pathology, Colorado State  
6 University, Fort Collins, CO 80523-1644, USA

7 Telephone: 970-297-1287

8 FAX: 970-297-0320

9 Email: [hvancamp@lamar.colostate.edu](mailto:hvancamp@lamar.colostate.edu)

10

11 Correspondence should be addressed to:

12 Hana Van Campen

13 Colorado State University Diagnostic Medical Center

14 300 West Drake Rd.

15 Fort Collins, CO 80523-1644

16 Telephone: 970-297-1287

17 FAX: 970-297-0320

18 Email: [hvancamp@lamar.colostate.edu](mailto:hvancamp@lamar.colostate.edu)

19

20

21 Key Words: Bovine viral diarrhea, epidemiology, U.S.

22

23

24

25 Abstract:

26           The apparent prevalence of bovine viral diarrhea virus (BVDV) persistently  
27 infected cattle has been found to be low in U.S. dairies, beef herds and feedlots. Current  
28 management practices within U.S. cattle industries that impact the epidemiology of  
29 BVDV infections include purchasing untested cattle, lack of biosecurity procedures, large  
30 herd sizes, mixing cattle from multiple sources, high cattle densities in dairy and feedlot  
31 operations, synchronous breeding of beef herds, communal grazing and widespread  
32 vaccination. Evidence for BVDV infection has been found in farmed and free-ranging  
33 wildlife in North America; however the risk of BVDV transmission from wildlife to  
34 cattle is not known. The perception of a low prevalence of BVDV herd infections, the  
35 unrestricted sale of PI cattle, lack of economic data, intensive marketing of vaccines,  
36 reluctance to accept federal regulations, and a “gambler’s” attitude among producers are  
37 impediments to implementation of a national systematic BVD control program. Since  
38 2004, voluntary BVDV control programs have been organized in nine states reflecting  
39 the recognition of BVD as an important and preventable problem in the U.S.

40

41 The Epidemiology of Bovine Viral Diarrhea Virus in the U.S.:

42           There are 104.3 million cattle in the U.S. distributed over 1 million farms,  
43 ranches, feedlots and other premises covering a broad spectrum of environments and  
44 diverse cattle production systems (NASS, 2008). While bovine viral diarrhea virus  
45 (BVDV) transmission and associated diseases are the same as found elsewhere,  
46 differences in cattle management practices in the U.S. result in clinical manifestations at

47 the herd level that are different from those observed in Europe, and which present  
48 challenges to controlling the viral infection.

49

50 Prevalence of BVDV infections in U.S. cattle.

51 An important difference between European cattle prior to the institution of bovine  
52 viral diarrhea (BVD) eradication programs, and the U.S. is the low prevalence of BVDV  
53 persistent infection in U.S. cattle. Data collected from recent surveys of beef cattle  
54 indicate that the prevalence of persistently infected (PI) animals in the U.S. cattle  
55 population is low,  $\leq 0.3\%$  in surveys of beef herds (Wittum et al., 2001; O'Connor et al.,  
56 2007), feedlots (Loneragan et al., 2005, Fulton et al., 2006), and dairies (Houe et al.,  
57 1995; Munoz-Zanzi et al., 2003). The prevalence of BVDV-infected beef herds, as  
58 defined by PI animal detection within herds, is 4% for beef cattle (Wittum et al., 2001;  
59 O'Connor et al., 2007). The prevalence of BVDV-infected dairy herds is 15% based on  
60 PI cattle detected in Michigan herds (Houe et al., 1995), and 1.7% in a national survey  
61 based on detecting BVDV by RT-PCR in bulk milk samples (USDA 2007). In the latter  
62 report, the percent of BVDV RT PCR positive dairy herds ranged from 0% in herds with  
63 less than 100 cows to 12.8% in herds with  $\geq 500$  cows.

64

65 The apparently low prevalence of BVDV-infected beef herds based on PI animal  
66 detection is likely to be an underestimate of true herd prevalence. Some BVDV-infected  
67 beef herds may be misclassified as uninfected herds if there is no PI animal alive at the  
68 time of testing. Test methods that are currently available do not detect PI fetuses, and the  
69 infection at the herd level continues when these calves are born. Surveying dairy herds

70 by reverse transcriptase-polymerase chain reaction (RT-PCR) assays of bulk milk  
71 samples may result in the misclassification of herds as uninfected if there are no PI  
72 animals in the lactating cow herd. This testing strategy underestimates the prevalence of  
73 infected herds as the young stock, which is not surveyed by this method, is more likely to  
74 include PI animals than older cattle.

75

76 Accurately determining the prevalence of BVDV infection in individual cattle or  
77 herds in the U.S. is problematic for a number of reasons. Herd sizes are relatively large  
78 and testing every individual animal is neither logistically or economically feasible.

79 Although testing strategies for pooled samples have been developed, they do not replace  
80 the need to obtain samples from each animal (Kennedy et al., 2006). An estimated 80%  
81 of cattle in the U.S. are vaccinated with either inactivated or modified live viral vaccines  
82 containing BVDV (USDA 1995; USDA 2007); consequently, BVDV seroprevalence is  
83 high, and the serologic tests are unable to distinguish between vaccinated and naturally  
84 infected cattle (Paisley et al., 1996). The testing strategies used in Europe to identify  
85 BVDV-infected herds based on serology are not useful in this situation as they would  
86 misclassify vaccinated-uninfected herds as being BVDV-infected. Thus, testing U.S.  
87 herds is a challenge for any rigorous BVD control program.

88

89 If the prevalence of BVDV-infected herds in the U.S. is truly low, then one could  
90 surmise that control of BVDV-associated diseases by eradication could be easily  
91 accomplished. The low prevalence, however, also means that a large proportion of U.S.  
92 herds are susceptible to the introduction of BVDV infections. As the sale of PI animals is

93 not prohibited, epidemics of BVDV-associated diseases occur each year as the viruses are  
94 introduced into these herds through the purchase of PI cattle or cows bearing PI fetuses.  
95 BVDV-associated diseases are not reportable and the diseases may be misdiagnosed;  
96 therefore, there is no data enumerating BVDV-associated cases. Occurrences of diseases  
97 are only captured in a few case reports.

98

99 Cattle management in the U.S. that impact BVDV infections:

100       The trend in U.S. dairies has been towards fewer farms and larger herd sizes. The  
101 rapid growth of large dairies has increased the demand for bred replacement heifers.  
102 Risk factors for herds with positive BVDV RT-PCR bulk milk tank samples include large  
103 herd size (>500 cows) and purchasing animals (USDA 2007). To meet the demand,  
104 heifers are raised and bred in commercial facilities where thousands of cattle from  
105 multiple origins are co-mingled. Contact with PI animals in these facilities during the  
106 breeding period generates PI fetuses. When these heifers return to dairies, they give birth  
107 to PI calves which then are a source of BVDV infection for the rest of the herd. Dairy  
108 herd expansion may occur more rapidly than optimal for the facilities and personnel  
109 resulting in crowding and insufficient attention to biosecurity and sanitation measures.  
110 Inadequate separation of pregnant cows from young stock including PI calves leads to  
111 additional fetal infections. In registered herds where the genetic value of individual  
112 animals is emphasized, PI cattle may be retained in the herd despite poor health and  
113 phenotype. (Rauff et al., 1996; Rush et al., 2001). Infertility as judged by the percent of  
114 cows >150 days open is higher (18.2%) for BVDV-infected operations compared to  
115 noninfected dairies (USDA 2007), and supports the finding that infertility in heifers has

116 been linked to congenital BVDV infection (Munoz-Zanzi et al., 2004). As infertility is  
117 an important factor in culling decisions made on dairies, a cycle of culling infertile cows  
118 necessitating increased purchases of at-risk heifers. BVDV RT-PCR positive dairies are  
119 more likely to use BVDV-containing vaccines than non-infected operations suggesting  
120 that vaccines are being used in response to problems perceived to be due to BVDV  
121 infections (USDA 2007). An important difference between dairy and beef herds with  
122 respect to the epidemiology of BVD is that breeding in dairy herds occurs over the entire  
123 year. Exposure of the cows to a PI animal results in the infection of fetuses whose ages  
124 cover the entire gestational period. Calves with congenital defects resulting from BVDV  
125 infection are more likely to be born into dairy herds which aids in recognition of herd  
126 infection.

127  
128 Beef herds engage in similar high risk practices as dairy herds including the  
129 purchase of untested cattle. The purchase of pregnant heifers and utilization of heifer  
130 development feedlots has become common in the beef industry and like the dairies,  
131 generate PI fetuses which then serve as the source of infection for the cow herd when the  
132 heifers return and calve. In addition, ranchers share summer pastures where cows in their  
133 first trimester of pregnancy may contact PI calves from other herds (Sanderson et al.,  
134 2000). The practice of synchronous, seasonal breeding in beef cattle has a marked impact  
135 on the manner in which BVDV-associated reproductive losses present. Contact with a  
136 single PI calf can infect a large proportion of cows during the first trimester of pregnancy.  
137 In this scenario, the first observation is a distinct rise in infertility cases determined at  
138 pregnancy examination. Typically, this is followed by explosive abortion “storm”

139 beginning one month prior to the planned calving interval and followed by increased  
140 stillbirths, the birth of stunted calves and weak, non-viable calves. In some cases, BVDV  
141 epidemics result in losses of 50% of the calf crop. In contrast to dairy herds, classic  
142 congenital defects such as cerebellar hypoplasia are infrequently observed in beef herds  
143 due to the early gestational age of fetuses at the time of exposure of cow-calf herds to PI  
144 calves.

145  
146         There are two possible outcomes following the epidemic year of BVDV infection.  
147 If a PI calf is not born or does not survive into the breeding season, then BVDV infection  
148 of the herd will not be sustained and the herd will be uninfected. Detection of BVDV  
149 antibodies in the cow herd at this point would falsely classify the herd as infected (Van  
150 Campen et al., 1998). Secondly, the herd can enter an endemic state of infection if a PI  
151 calf survives into the breeding season. In endemically infected beef herds, approximately  
152 50% of the calves will have become infected by the time they are weaned due to contact  
153 with PI calves present in the same cohort (Cleveland et al., 2004). Calfhood infections  
154 may be clinically inapparent during the period that the calf is protected by maternal  
155 antibodies, but manifest as diarrhea and pneumonia when maternal antibodies wane. The  
156 rest of the calf crop may be impacted by BVDV in more subtle ways such as lower  
157 weaning weights and rate of gain (Waldner and Kennedy, 2008). In either scenario,  
158 cows rendered immune by the initial infection will protect subsequent pregnancies from  
159 antigenically similar BVD viruses for the rest of their life. Their offspring will not be PI  
160 or suffer other consequences of congenital infection; however, their offspring will be  
161 susceptible to infection. If susceptible heifers are retained in the herd and remain

162 unexposed, e.g., by virtue of being raised separately from the cow herd, they serve as the  
163 source of additional PI animals following exposure to PI calves when they enter the cow  
164 herd and are bred.

165

166 On average, 10,000,000 head of cattle are on feed in the U.S. in just under  
167 1,000,000 premises. Approximately one-third of the inventory is fed in feedlots with  
168 over 1,000 head of cattle (NAAS 2008). By necessity, maintaining this inventory  
169 requires purchasing cattle from multiple sources and co-mingling animals at high animal  
170 densities. In addition, calves pass through several sales facilities prior to entry into the  
171 yard which represents another opportunity for exposure to pathogens. The percentage of  
172 PI cattle entering feedlots is low; however, cattle in adjacent pens as well as with the  
173 home pen are subject to infection. In some cases, the immunosuppressive effects of  
174 BVDV likely play a role in increased risk of morbidity and mortality due to respiratory  
175 disease (Loneragan et al. 2005). However, other surveys of beef cattle failed to find any  
176 significant effect of PI calves on herd health (O'Connor et al., 2007). In terms of  
177 transmission, the feedlot is an endpoint for the viruses, and would not impact their  
178 maintenance in the breeding cattle population. The economic impact on feeder calves is  
179 more easily apparent which explains the interest in BVDV control from this segment of  
180 the cattle industry.

181

182 Wildlife and other sources of BVDV:

183 The U.S. enjoys ample populations of wild species of ruminants which share  
184 range and forage with domestic cattle. Serologic surveys have indicated that these

185 animals become infected with BVDV and other pestiviruses (reviewed by Van Campen et  
186 al., 2001a). Evidence for PI white-tailed and mule deer have been found in several states  
187 (Chase et al., 2008; Duncan et al., 2008b; Pogranichniy, et al., 2008; Van Campen et al.,  
188 2001b), and PI white-tailed fawns have been generated experimentally by the inoculation  
189 of pregnant does (Duncan et al., 2008a). Clearly, free-ranging wildlife species are a  
190 potential source of infection for cattle; however, transmission from wildlife to cattle has  
191 not been demonstrated to have occurred in nature and the risks of infection from this  
192 source have not been examined. Recently, the persistent infection of alpacas with a  
193 noncytopathic type 1b BVDV was reported (Carman et al., 2005). The monetary value  
194 placed on individual alpacas, the aggressiveness with which breed associations pursued  
195 PI testing and the small number of PI crias identified makes this species an unlikely  
196 source of infection for cattle. Few surveys of Pestivirus infections have been conducted  
197 in domestic sheep and goats in the U.S. that might indicate the extent of these infections  
198 or whether these populations pose a risk to cattle.

199

#### 200 BVDV Control and Eradication Programs in the U.S.:

201 Prior to 2004, BVDV control largely rested on the use of inactivated and modified  
202 live BVDV vaccines. For decades, BVDV vaccines included either the Singer or NADL  
203 cytopathic type 1a BVD viruses. These vaccines were used to prevent both fetal  
204 infections with accompanying reproductive losses as well as to prevent diseases due to  
205 acute infections. The recognition of type 2 BVDV associated with severe disease and  
206 occurrence of fetal losses in vaccinated cows (Van Campen et al., 2000) led to the  
207 inclusion of a cytopathic type 2 BVDV in many vaccines. Since then experimental

208 challenge of vaccinated cows has established the superiority of MLV BVDV vaccines in  
209 providing fetal protections; however, concerns about safety and subtle effects of live viral  
210 vaccines on health remain a factor in their use (Ellsworth et al., 2006; Grooms et al.,  
211 2007; Schnackel et al., 2007). A significant consequence of the widespread use of  
212 BVDV vaccines is the inability to use serologic techniques for the diagnosis of BVD herd  
213 infections and for surveillance purposes in U.S. cattle. As important is the perception by  
214 producers that BVDV vaccines will prevent the introduction of BVDV into their herds.  
215 Given this mindset, biosecurity measures to prevent the introduction of BVDV and other  
216 pathogens are often ignored.

217

218 In 2003, the Academy of Veterinary Consultants published a position statement  
219 promoting the control and eventual eradication of BVD from the U.S. ([http://www.avc-](http://www.avc-beef.org/links/BVDLinks.asp)  
220 [beef.org/links/BVDLinks.asp](http://www.avc-beef.org/links/BVDLinks.asp)). This announcement was followed in Jan. 2004 by  
221 development of a voluntary BVD control program offered in conjunction with Colorado  
222 State University  
223 ([http://www.dlab.colostate.edu/BVDControlProgram/bvdcontrolprog\\_main.cfm](http://www.dlab.colostate.edu/BVDControlProgram/bvdcontrolprog_main.cfm)). Since  
224 then, the number of BVD prevention and control programs has expanded to include  
225 Alabama (<http://www.aces.edu/counties/Marion/files/bvd.pdf>), Georgia, Mississippi  
226 ([http://www.mbah.state.ms.us/disease\\_programs/bvd/MS\\_PI\\_BVD\\_Program.pdf](http://www.mbah.state.ms.us/disease_programs/bvd/MS_PI_BVD_Program.pdf)),  
227 Montana ([http://www.mtbqa.org/news/2007%20Montana%20BVD-](http://www.mtbqa.org/news/2007%20Montana%20BVD-PI%20Herd%20Screening%20Project.doc)  
228 [PI%20Herd%20Screening%20Project.doc](http://www.mtbqa.org/news/2007%20Montana%20BVD-PI%20Herd%20Screening%20Project.doc)), Oregon  
229 (<http://ans.oregonstate.edu/bvd/index.html>) and Washington  
230 (<http://www.vetmed.wsu.edu/bvdcep/>) with a focus on beef herds. New York has a BVD

231 control module offered through their extension service that is tailored to dairy farms  
232 (<http://nyschap.vet.cornell.edu/module/bvd/bvd.asp>). An exciting addition to this list is  
233 the BVD eradication program  
234 ([http://www.msue.msu.edu/workspaces/one.cfm?workspace\\_id=28413&object\\_id=45518](http://www.msue.msu.edu/workspaces/one.cfm?workspace_id=28413&object_id=45518)  
235 1) offered to beef and dairy herds in the Upper Peninsula of Michigan through the  
236 extension service of Michigan State University.

237  
238 All programs are voluntary, associated with a university and organized in  
239 conjunction with other beef or dairy quality assurance programs. Program elements  
240 include: 1) education about BVDV transmission and diseases, 2) required testing  
241 procedures, 3) documentation of biosecurity practices to prevent the re-introduction of  
242 BVDV, and 4) verified use of a vaccination schedule. A wide range of resources are  
243 available to veterinarians, diagnosticians and producers seeking information about the  
244 control and prevention of BVDV infections. These subjects have continued to receive  
245 extensive coverage in magazines and the websites of veterinary medical and producer  
246 organizations, by university extension personnel and vaccine companies. Consultation on  
247 BVD control is provided at no cost to the producer by extension personnel, clinical  
248 faculty at veterinary teaching hospitals and by diagnostic laboratories. Two BVD  
249 control programs have funding for to partially cover the costs of testing and limited  
250 funding for indemnification of owner's of PI animals. The biosecurity requirement in  
251 some programs means the development of a written biosecurity plan by each producer,  
252 and the systematic element of follow-up testing in subsequent years is encouraged.  
253 Funding the existing programs is a constant challenge. To date, BVD control programs

254 have relied on grants from producer organizations, state departments of agriculture,  
255 vaccine and pharmaceutical companies, and university resources.

256         Currently mandatory, systematic BVD control programs similar those in several  
257 European countries do not exist in the U.S. (Lindberg et al., 2006). The concept of BVD  
258 control by eradication has been slow to find acceptance in the U.S. Impediments include  
259 reluctance to institute a government-regulated control program. Available data indicating  
260 a low prevalence of BVDV infection in beef and dairy herds and uncertainty on the part  
261 of individual producers about the economic benefits of BVDV control. The lack of a  
262 clear danger is compounded by the “Gambler’s” mentality among individual cattle  
263 producers. The low herd prevalence validates the general belief that the application of  
264 BVDV vaccines is a “cure-all” rather than an aid in prevention of BVDV infections.  
265 However, producers and veterinarians who have experienced losses due to BVDV-  
266 associated diseases are more motivated to adopt preventive measures. Producer and  
267 veterinarians’ awareness of the potential impact is the impetus behind the BVDV testing  
268 recently adopted by bull sales, purebred stock sales, livestock shows and specific  
269 feedlots. The proliferation of BVD control and eradication programs in the U.S. is  
270 encouraging and highlights recognition of BVDV’s importance to cattle health.

271

272

273 References:

274

- 275 Carman, S., Carr, N., DeLay, J., Baxi, M., Deregt, D., Hazlett, M. 2005. Bovine viral  
276 diarrhea virus in alpaca: abortion and persistent infection. *J Vet Diagn Invest* 17, 589-  
277 593.
- 278
- 279 Chase, C.L.C., Braun, L.J., Leslie-Steen, P., Graham, T., Miskimins, D., Ridpath, J.F.  
280 2008. Bovine viral diarrhea virus multiorgan infection in two white-tailed deer in  
281 southeastern South Dakota. *J. Wildl. Dis.* 44, 753-759.
- 282
- 283 Cleveland, S. M., Cleveland, M. A., Salman, M. D., Mortimer, R. G., Van Campen, H.  
284 2004. Removal of bovine viral diarrhea virus persistently infected animals from an  
285 endemically infected beef herd: effect on PI animal prevalence and BVDV  
286 seroprevalence. *Bovine Practitioner* 38(2), 155-160
- 287
- 288 Duncan C, Ridpath J, Palmer MV, Driskell E, Spraker T. 2008a. Histopathologic and  
289 immunohistochemical findings in two white-tailed deer fawns persistently infected with  
290 Bovine viral diarrhea virus. *J Vet Diagn Invest.* 20, 289-96.
- 291
- 292 Duncan, C., Van Campen, H., Soto, S, LeVan, I.K., Baeten, L.A., Miller, M.W. 2008b.  
293 Persistent bovine viral diarrhea virus infection in wild cervids of Colorado. *J Vet Diagn*  
294 *Invest* 20, 650-653.
- 295
- 296 Ellsworth, M.A., Fairbanks, K.K., Behan, S., Jackson, J.A., Goodyear, M., Oien, N.A.,  
297 Meinert, T.R., Leyh, R.D. 2006. Fetal protection following exposure to calves

298 persistently infected with bovine viral diarrhea virus type 2 sixteen months after primary  
299 vaccination of the dams. *Vet Ther.* 7, 295-304.

300

301 Fulton, R.W., Hessman, B., Johnson, B.J., Ridpath, J.F., Saliki, J.T., Burge, L.J.,  
302 Sjeklocha, D., Confer, A.W., Funk, R.A. Payton, M.E. 2006. Evaluation of diagnostic  
303 tesets used for detection of bovine viral diarrhea virus and prevalence of subtypes 1a, 1b,  
304 and 2a in persistently infected cattle entering a feedlot. *JAVMA* 228, 578-584.

305

306

307 Grooms, D. L., Bolin, S. R., Coe, P.H., Borges, R.J., Coutu, C. E. 2007. Fetal protection  
308 against continual exposure to bovine viral diarrhea virus following administration of a  
309 vaccine containing an inactivated bovine viral diarrhea virus fraction to cattle. *Am J Vet*  
310 *Res* 68: 1417-1422.

311

312 Houe, H., Baker, J.C., Maes, R.K., Wiryastuti, H., Wasito, R., Ruegg, P.L. Lloyd, J.W.  
313 1995. Prevalence of cattle persistently infected with bovine viral diarrhea virus in 20  
314 dairy herds in tow counties in central Michigan and comparison of prevalence of  
315 antibody-positive cattle among herds with different infection and vaccination status. *J Vet*  
316 *Diagn Invest* 7, 321-326.

317

318 Kennedy, J.A., Mortimer, R.G., Powers, B. 2006. Reverse transcription-polymerase chain  
319 reaction on pooled samples to detect bovine viral diarrhea virus by using fresh ear-notch-  
320 sample supernatants. *J Vet Diagn Invest* 18, 89-93.

321

322 Lindberg, A., Brownlie J, Gunn GJ, Houe H, Moennig V, Saatkamp HW, Sandvik T,  
323 Valle PS. 2006. The control of bovine viral diarrhoea virus in Europe: today and in the  
324 future. *Rev Sci Tech.* 25, 961-79.  
325

326 Loneragan, G. H., Thomson, D. U., Montgomery, D.L., Mason, G. L., Larson, R.L. 2005.  
327 Prevalence, outcome, and health consequences associated with persistent infection with  
328 bovine viral diarrhea virus in feedlot cattle. *JAVMA* 226(4), 595-601.  
329

330 Munoz-Zanzi, C. A., Hietala, S. K., Thurmond, M. C., Johnson, W.O. 2003.  
331 Quantification, risk factors and health impact of natural congenital infection with bovine  
332 viral diarrhea virus in dairy calves. *Am J Vet Res* 64(3), 358-365.  
333

334 Munoz-Zanzi, C. A., Hietala, S. K., Thurmond, M. C., Johnson, W.O. 2004. Effect of  
335 bovine viral diarrhea virus infection on fertility of dairy heifers. *Theriogenology* 61(6),  
336 1085-1099.  
337

338 National Agricultural Statistics Service, Agriculture Statistics Board, USDA.  
339 <http://www.nass.usda.gov/index.asp>  
340

341 O'Connor, A.M., Reed, M. C., Denagamage, T. N., Yoon, K.-J., Sorden, S.D. 2007.  
342 Prevalence of calves persistently infected with bovine viral diarrhea virus in beef cow-  
343 calf herds enrolled in a voluntary screening project. *JAVMA* 230(11), 1691-1696.  
344

- 345 Paisley, L. G., Wells, S., Schmitt, B.J. 1996. Prevalence of bovine viral diarrhea  
346 antibodies in 256 U.S. cow-calf operations: a survey. *Theriogenology* 46, 1313-1323.  
347
- 348 Pogranichniy RM, Raizman E, Thacker HL, Stevenson GW. 2008. Prevalence and  
349 characterization of bovine viral diarrhea virus in the white-tailed deer population in  
350 Indiana. *J Vet Diagn Invest.* 20,71-74.  
351
- 352 Rauff, Y., Moore, D. A., Sischo, W.M. 1996. Evaluation of the results of a survey of  
353 dairy producers on dairy herd biosecurity and vaccination against bovine viral diarrhea.  
354 *JAVMA* 210, 1618-1622.  
355
- 356 Rush, D.M., Thurmond, M.C., Munoz-Zanzi, C.A., Hietala, S.K. 2001. Descriptive  
357 epidemiology of postnatal bovine viral diarrhea virus infection in intensively managed  
358 dairy heifers. *JAVMA* 219, 1426-1431.  
359
- 360 Sanderson, M. W., Dargatz, D. A., Garry, F.B. 2000. Biosecurity practices of beef cow-  
361 calf producers. *JAVMA* 217, 185-189.  
362
- 363 Schnackel, J. Van Campen, H., van Olphen, A. 2007. Modified-live bovine viral diarrhea  
364 virus (BVDV) type 1a vaccine provides protection against fetal infection after challenge  
365 with either type 1b or type 2 BVDV. *The Bovine Practitioner* 41, 1-8.  
366
- 367 USDA. 1995. Vaccination practices for respiratory pathogens in U.S. Feedlots. USDA-  
368 APHIS-VS, CEAH. Fort Collins, CO #N176.0295

369

370 USDA. 2007. Dairy 2007, Part III: Reference of Dairy Cattle Health and Management  
371 Practices in the United States, 2007. USDA–APHIS–VS, CEAH. Fort Collins, CO  
372 #N482.0608, <http://www.aphis.usda.gov/vs/ceah/ncahs/nahms/dairy/index.htm>

373

374 Van Campen, H., Huzurbazar, S., Edwards, J., Cavender, J. 1998. Distribution of  
375 antibody titers to bovine viral diarrhea virus in infected, exposed and uninfected beef  
376 cattle. *J Vet Diagn Invest* 10, 183-186.

377

378 Van Campen, H., Vorpahl, P., Huzurbazar, S., Edwards, J., Cavender, J. 2000. A case  
379 report: Evidence for BVDV type 2-associated disease in beef herds vaccinated with a  
380 MLV-BVDV Type 1 vaccine. *J Vet Diagn Invest* 12, 263-265.

381

382 Van Campen, H., Frolich, K., M. Hofmann. 2001a. Pestivirus infections. *In: Infectious*  
383 *Diseases of Wild Mammals*, 3<sup>rd</sup> Ed., Williams, E.S. and I.K. Barker, (eds). Iowa State  
384 Univ. Press, Ames, IA.

385

386  
387 Van Campen, H., Ridpath, J., Williams, E., Cavender, J., Edwards, J., Smith, S., Sawyer,  
388 H.H. 2001b. Isolation of bovine viral diarrhea virus from a free-ranging mule deer  
389 (*Odocoileus hemionus*). *Journal of Wildlife Diseases* 37, 306-311.

390

391 Van Campen, H, Vorpahl, P, Huzurbazar, S. Edwards, J., Cavender, J. 2001c. A case  
392 report: Evidence for type 2 bovine viral diarrhea virus (BVDV)-associated disease in

393 beef herds vaccinated with a modified-live type 1 BVDV vaccine. J Vet Diagn Invest 12,  
394 263-265.

395

396 Waldner, C. L., Kennedy, R.I. 2008. Associations between health and productivity in  
397 cow-calf beef herds and persistent infection with bovine viral diarrhea virus, antibodies  
398 against bovine viral diarrhea virus, or antibodies against infectious bovine rhinotracheitis  
399 virus in calves. AJVR 69, 916-927.

400

401 Wittum, T. E., Grotelueschen, D. M., Brock, K. V., Kvasnicka, W. G., Floyd, J. G.,  
402 Kelling, C. L., Odde, K.G. 2001. Persistent bovine viral diarrhea virus infection in US  
403 beef herds. Prev Vet Med 49, 83-94.

404

405 Acknowledgements: The author would like to thank the organizers of the 7<sup>th</sup> ESVV  
406 Pestivirus Symposium for their invitation and encouragement.

407

408 Conflict of interest statement: The author is employed by Colorado State University and  
409 works in the Veterinary Diagnostic Laboratory, Ft. Collins, CO. She collaborates with  
410 investigators with grants funded by USDA, NRI and Pfizer Animal Health.